Immuron (IMRN) Earns Media Sentiment Rating of 0.18

News coverage about Immuron (NASDAQ:IMRN) has been trending somewhat positive on Monday, Accern Sentiment reports. The research firm identifies positive and negative press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Immuron earned a news sentiment score of 0.18 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 45.3496248567175 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Immuron (NASDAQ IMRN) traded down $0.20 during trading hours on Monday, reaching $4.86. The company had a trading volume of 3,040 shares, compared to its average volume of 17,004. Immuron has a 12-month low of $4.47 and a 12-month high of $16.34.

Separately, HC Wainwright initiated coverage on Immuron in a report on Wednesday, October 18th. They set a “buy” rating and a $15.00 price target on the stock.

COPYRIGHT VIOLATION NOTICE: “Immuron (IMRN) Earns Media Sentiment Rating of 0.18” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece of content can be accessed at

About Immuron

Immuron Limited, a microbiome company, focuses on developing and commercializing oral immunotherapeutics for the treatment of various gut medicated diseases in Australia and internationally. The company operates through Research and Development, and HyperImmune Products segments. It has a technology platform that enables a shorter development therapeutic cycle.

Insider Buying and Selling by Quarter for Immuron (NASDAQ:IMRN)

Receive News & Ratings for Immuron Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immuron Ltd and related companies with's FREE daily email newsletter.

Leave a Reply